Bover J, Aguilar A, Arana C, Molina P, Lloret M, Ochoa J
Front Med (Lausanne). 2021; 8:642718.
PMID: 34095165
PMC: 8171667.
DOI: 10.3389/fmed.2021.642718.
Torregrosa J, Ferreira A, Cucchiari D, Ferreira A
Calcif Tissue Int. 2021; 108(4):551-560.
PMID: 33765230
DOI: 10.1007/s00223-021-00837-0.
Cannata-Andia J, Martin-Carro B, Martin-Virgala J, Rodriguez-Carrio J, Bande-Fernandez J, Alonso-Montes C
Calcif Tissue Int. 2020; 108(4):410-422.
PMID: 33190187
DOI: 10.1007/s00223-020-00777-1.
Villa-Bellosta R, Mahillo-Fernandez I, Ortiz A, Gonzalez-Parra E
Nutrients. 2019; 11(5).
PMID: 31035488
PMC: 6566618.
DOI: 10.3390/nu11050959.
Rodelo-Haad C, Rodriguez-Ortiz M, Martin-Malo A, Pendon-Ruiz de Mier M, Aguera M, Munoz-Castaneda J
PLoS One. 2018; 13(8):e0201537.
PMID: 30086150
PMC: 6080760.
DOI: 10.1371/journal.pone.0201537.
25(OH)D3-enriched or fortified foods are more efficient at tackling inadequate vitamin D status than vitamin D3.
Guo J, Lovegrove J, Givens D
Proc Nutr Soc. 2017; 77(3):282-291.
PMID: 29173203
PMC: 6088524.
DOI: 10.1017/S0029665117004062.
Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
Bover J, Bailone L, Lopez-Baez V, Benito S, Ciceri P, Galassi A
J Nephrol. 2017; 30(5):677-687.
PMID: 28432640
DOI: 10.1007/s40620-017-0404-z.
Vascular calcification: When should we interfere in chronic kidney disease patients and how?.
Sharaf El Din U, Salem M, Abdulazim D
World J Nephrol. 2016; 5(5):398-417.
PMID: 27648404
PMC: 5011247.
DOI: 10.5527/wjn.v5.i5.398.
A New Data Analysis System to Quantify Associations between Biochemical Parameters of Chronic Kidney Disease-Mineral Bone Disease.
Rodriguez M, Salmeron M, Martin-Malo A, Barbieri C, Mari F, Molina R
PLoS One. 2016; 11(1):e0146801.
PMID: 26808154
PMC: 4726537.
DOI: 10.1371/journal.pone.0146801.
Comparison of two different vitamin D supplementation regimens with oral calcifediol in kidney transplant patients.
Barros X, Rodriguez N, Fuster D, Rodas L, Esforzado N, Mazza A
J Nephrol. 2015; 29(5):703-9.
PMID: 26454858
DOI: 10.1007/s40620-015-0237-6.
Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.
Bover J, Urena P, Ruiz-Garcia C, DaSilva I, Lescano P, Del Carpio J
Clin J Am Soc Nephrol. 2015; 11(1):161-74.
PMID: 26224878
PMC: 4702220.
DOI: 10.2215/CJN.01760215.
Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis.
Gros B, Galan A, Gonzalez-Parra E, Herrero J, Echave M, Vegter S
Health Econ Rev. 2015; 5(1):49.
PMID: 26062537
PMC: 4467815.
DOI: 10.1186/s13561-015-0049-3.
[Consensus document for the detection and management of chronic kidney disease].
Martinez-Castelao A, Gorriz J, Bover J, Segura-de la Morena J, Cebollada J, Escalada J
Aten Primaria. 2014; 46(9):501-19.
PMID: 25288498
PMC: 6983829.
DOI: 10.1016/j.aprim.2014.09.002.
Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence.
Lloret M, Ruiz-Garcia C, DaSilva I, Furlano M, Barreiro Y, Ballarin J
Patient Prefer Adherence. 2013; 7:1147-56.
PMID: 24235818
PMC: 3826937.
DOI: 10.2147/PPA.S31694.
